Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?

Documenti analoghi

• Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
  di: Mienko, Fiona, et al.
  Pubblicazione: (2020)
• Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
  di: Sgambato, Assunta, et al.
  Pubblicazione: (2014)
• Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question
  di: Gridelli, Cesare, et al.
  Pubblicazione: (2016)
• Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
  di: Theelen, Willemijn S. M. E., et al.
  Pubblicazione: (2019)
• J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
  di: Gridelli, Cesare, et al.
  Pubblicazione: (2018)